➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Dow
McKesson
Mallinckrodt
Colorcon
Boehringer Ingelheim

Last Updated: October 18, 2021

DrugPatentWatch Database Preview

PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN Drug Patent Profile


Email this page to a colleague

« Back to Dashboard

Which patents cover Propoxyphene Hydrochloride And Acetaminophen, and when can generic versions of Propoxyphene Hydrochloride And Acetaminophen launch?

Propoxyphene Hydrochloride And Acetaminophen is a drug marketed by Mylan, Sandoz, Vintage Pharms, and Watson Labs. and is included in five NDAs.

The generic ingredient in PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN is acetaminophen; propoxyphene hydrochloride. There are sixty-six drug master file entries for this compound. Additional details are available on the acetaminophen; propoxyphene hydrochloride profile page.

Summary for PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN
Drug patent expirations by year for PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN
Recent Clinical Trials for PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Mansoura UniversityPhase 1/Phase 2
Fundação de Amparo à Pesquisa do Estado de São PauloPhase 4
Federal University of São PauloPhase 4

See all PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN clinical trials

US Patents and Regulatory Information for PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN acetaminophen; propoxyphene hydrochloride TABLET;ORAL 083689-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Vintage Pharms PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN acetaminophen; propoxyphene hydrochloride TABLET;ORAL 040507-001 Jul 30, 2003 DISCN No No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Mylan PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN acetaminophen; propoxyphene hydrochloride TABLET;ORAL 083978-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Sandoz PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN acetaminophen; propoxyphene hydrochloride TABLET;ORAL 089959-001 Jul 18, 1989 DISCN No No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Watson Labs PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN acetaminophen; propoxyphene hydrochloride TABLET;ORAL 040139-001 Dec 16, 1996 DISCN No No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Dow
McKesson
Mallinckrodt
Colorcon
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.